National procurement of insulin is approaching, and such companies will escort product quality

At present, the sixth batch of national procurement (special collection of insulin) has completed the reporting work in all provinces across the country
.
According to the schedule, we will then enter the stage of issuing centralized procurement documents, and we will begin to clarify the time and location of bid opening one after another
.
According to the schedule of the consultation draft, this centralized procurement is expected to be implemented in early 2022 with a two-year cycle
.
The national procurement of insulin is approaching, and pharmaceutical equipment will escort product quality (picture source: Pharmaceutical Network) It is understood that there are a total of 81 products in the national procurement of insulin, involving Novo Nordisk, Eli Lilly, Sanofi, Tonghua Dong Bao, Tianmai Biological, Ganli Pharmaceutical, Zhuhai United Laboratories, Yuheng Pharmaceutical, Wanbang Biochemical and Dongyang Sunshine have a total of 10 companies, involving a market size of 27 billion
.
The industry believes that the arrival of the national procurement of insulin means that there will be more room for domestically produced insulin to replace imported insulin.
While more development opportunities are ushered in, it will also face major challenges
.
For example, in the face of national procurement, relevant pharmaceutical companies need to think about how to transform and upgrade, and use policies to reduce costs, control prices, improve product quality, and expand market share
.
It is worth noting that in this context, some people in the industry have suggested that insulin production equipment companies may benefit
.
It is reported that as an upstream industry, pharmaceutical equipment has always been closely related to pharmaceutical production
.
For insulin pharmaceutical companies, with the continuous deepening of volume purchases, the demand for capacity expansion by bid-winning pharmaceutical companies is expected to continue to increase
.
However, in the context of centralized drug procurement and price reduction, it will also face increasingly stringent regulatory pressures in terms of production capacity and quality assurance
.
Therefore, how to achieve cost control and ensure production capacity and supply stability will become the main challenges in the development of these pharmaceutical companies
.
The analysis believes that in response to the above situation, pharmaceutical equipment will play a role in helping insulin pharmaceutical companies liberate more productivity and improve production efficiency in this process
.
According to the author’s understanding, with the current accelerated development of intelligence, automation, and informatization, the pharmaceutical equipment industry has actually begun to grasp new trends and new technologies, and constantly optimize and upgrade, so that the equipment can achieve greater value while doing better.
Stable production capacity and supply of pharmaceutical companies escorted
.
In addition, in recent years, in order to promote the high-quality development of the pharmaceutical industry, the country has been advocating green production
.
However, it should be noted that the wastewater produced by insulin has always had problems such as complex composition, high concentration of organic matter, and high salinity, and it needs to be treated before it can be discharged or continue to be used
.
Therefore, in order to meet environmental protection requirements, the demand for wastewater treatment equipment by relevant pharmaceutical companies will further increase, and this will also bring more opportunities for relevant equipment companies
.
At present, in the face of the increasing demand for wastewater treatment equipment by pharmaceutical companies, the industry has begun to conduct continuous basic research and collaborative cooperation between industry, university and research
.
Based on this, a number of practical technologies and equipment have also been successfully applied in the pharmaceutical industry and achieved good results
.
For example, equipment companies focus on the treatment of chemical wastewater and pharmaceutical wastewater, aiming at high-salt wastewater, with 3D electrode equipment as the core, and develop a set of high-efficiency treatment processes that can recover resources and reduce energy consumption
.
According to reports, the process can efficiently remove salt, extract acid and alkali, improve the biodegradability of wastewater, and achieve the purpose of resource recovery.
It has the characteristics of high efficiency, energy saving, and no solid waste generation.
It is suitable for chemical, pharmaceutical and other industries
.
Generally speaking, the pharmaceutical equipment industry is closely related to pharmaceutical companies.
With the continuous expansion of the insulin market and the further increase in concentration, it is bound to have a lot to do
.
However, it should be noted that the technical level and functions of the equipment are always the focus of pharmaceutical companies.
Therefore, pharmaceutical equipment companies need to continuously improve their innovation capabilities and technologies to develop higher-quality equipment to meet the needs of insulin companies.
More demand and help its compliance development
.